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Abstract
High-throughput genetic and epigenetic data are often screened for
associations with an observed phenotype. For example, one may wish to
test hundreds of thousands of genetic variants, or DNA methylation sites,
for an association with disease status. These genomic variables can natu-
rally be grouped by the gene they encode, among other criteria. However,
standard practice in such applications is independent screening with a
universal correction for multiplicity. We propose a Bayesian approach in
which the prior probability of an association for a given genomic vari-
able depends on its gene, and the gene-specific probabilities are modeled
nonparametrically. This hierarchical model allows for appropriate gene
and genome-wide multiplicity adjustments, and can be incorporated into
a variety of Bayesian association screening methodologies with negligi-
ble increase in computational complexity. We describe an application to
screening for differences in DNA methylation between lower grade glioma
and glioblastoma multiforme tumor samples from The Cancer Genome
Atlas. Software is available via the package BayesianScreening for R:
github.com/lockEF/BayesianScreening.
1 Introduction
Several technologies that are used for genomic research measure data that are
high-throughput and genome-wide. These data may be genetic or epigenetic.
Technologies that measure genetic data include single nucleotide polymorphism
(SNP) arrays, whole-exome sequencing, and whole-genome sequencing; tech-
nologies that measure epigenetic data include DNA methylation bisulphite ar-
rays or bisulphite sequencing, and chromatin immunoprecipitation sequencing
(ChIP-seq). These technologies all measure hundreds of thousands of variables,
1
ar
X
iv
:1
60
4.
08
65
4v
1 
 [s
tat
.M
E]
  2
9 A
pr
 20
16
each of which can be mapped to a location on the genome. In this article we
use the general term “marker” to refer to any such variable.
A recurring objective in genomic research is to test each marker for an associ-
ation with a given phenotypic trait, such as disease status. These are commonly
conducted in a frequentist framework, where a p-value for the null hypothesis
of no association is calculated independently for each marker. Several thousand
such studies have been conducted for genetic associations alone [Welter et al.,
2014]. While these studies have revealed several important biomarkers, they
have also been criticized for lack of power and lack of reproducibility [Visscher
et al., 2012]. The reliance on p-values and binary conclusions may be partly
responsible for these criticisms. P-values are a poor proxy for our degree of
confidence that a true association exists, because they depend on the power of
the test [Stephens and Balding, 2009]. Furthermore, standard corrections for
multiple comparisons that control the family-wise error rate or false discovery
rate for a single study typically require exorbitant effect sizes, leaving most
associated markers undetected [Park et al., 2010].
As an alternative to frequentist-based approaches, several methodologies
have been developed to screen for genome-wide associations in a fully Bayesian
framework (for a review see Stephens and Balding [2009]), and these are in-
creasingly used in practice. Bayesian approaches directly compute the posterior
probability that a marker is associated with a given trait, under a full prob-
abilistic model for both the null and alternative hypotheses. This provides a
straightforward and intuitive framework for meta-analyses that combine results
from multiple studies [Verzilli et al., 2008, Wen et al., 2014]. Moreover, Bayesian
approaches provide a natural framework for borrowing information across mul-
tiple related markers within a single study to compute more well-informed and
accurate weights of evidence in the form of posterior probabilities. Importantly,
Bayesian techniques that combine multiple related tests need not treat the null
and alternative hypotheses asymmetrically; this is in contrast to frequentist ap-
proaches to the multiple comparisons problem that typically require larger effect
sizes for the alternative as the number of tests grows.
Despite their potential flexibility for borrowing information, standard prac-
tice for Bayesian genome-wide testing is to screen each marker independently.
This involves specifying a prior probability for association at each marker [Stephens
and Balding, 2009], or effectively fixing the prior probability at 0.5 and consid-
ering the Bayes factor for each marker [Wakefield, 2009, Xu et al., 2012]. Alter-
natively, the prior probability of association at each marker can be treated as
unknown (with, for example, a Beta(a, b) prior distribution) and inferred during
posterior computation [Scott et al., 2010, Lock and Dunson, 2015]. However,
this approach still relies on the over-simplified premise that the probability of
association is the same for all markers.
In this article, we describe a computationally scalable and widely applicable
approach to inferring null probabilities that depend on the genomic location of
each marker. Specifically, the prior probability of association for a given marker
depends on the gene it encodes. The gene-specific probabilities are modeled
with a nonparametric distribution that allows for appropriate genome-wide ad-
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justments for multiplicity. We demonstrate how this approach can dramatically
improve posterior accuracy and interpretation when there is gene-level depen-
dence among tests.
We apply our approach to an epigenome-wide association study of cancer-
ous brain tumors that develop from astrocyte cells. Specifically, we use DNA
methylation data from the Illumina HumanMethylation450 array to compare
methylation profiles between lower-grade astrocytoma and glioblastoma multi-
forme samples from The Cancer Genome Atlas. These data include methylation
measurements at 294, 093 genomic sites that map to 24, 358 different genes.
We apply our gene-level dependence model in conjunction with a previously
described method for screening for differential distribution between groups in
methylation array data based on shared kernels [Lock and Dunson, 2015]. Our
analysis reveals systematic differences in methylation distribution at a large
number of genomic sites, and the proportion of sites with differential methyla-
tion varies substantially between genes.
1.1 Gene-wise Association Tests
Many methods have been developed that combine multiple markers within a
single gene to test for an association at the gene level. For example, there is
a wide body of literature on methods that aggregate genetic variants within
a gene, via a direct sum or a regression model, to obtain a p-value for the
null hypothesis that the gene has no association with the given phenotype [Pan
et al., 2014, Wu et al., 2011, Liu et al., 2010]. Similarly, there are methods
that combine methylation markers within a given gene (or region) to obtain a
composite p-value [Wang et al., 2012]. These methods can substantially increase
power if many markers within a gene have a weak association that cannot be
detected independently [Wojcik et al., 2015], and also reduce the number of
overall tests for multiplicity correction. However, aggregating at the gene level
may miss important marker-specific effects; for example, different mutations
within the same gene can have very different phenotypic consequences [Rowntree
and Harris, 2003].
In a Bayesian framework, Wilson et al. [2010] describe a genome-wide model
for the association of genetic markers with an observed phenotype, in which
the Bayes factor for model inclusion can be computed at the marker or gene
level. In their implementation each marker has the same prior probability of
association p genome-wide, with hyperprior p ∼ Beta(a, b); a gene is considered
associated with the observed phenotype if any marker within the gene is associ-
ated. Alternatively, Ruklisa et al. [2015] describe a class of Bayesian approaches
to rare variant association testing in which the prior probability that a given
marker is associated depends on the gene it encodes. For their approach the
gene-specific probabilities are estimated independently based on training data,
with no borrowing of information across the genes. Nevertheless, they illustrate
that gene-specific probabilities can outperform genome-wide approaches.
In this article we describe a flexible compromise between genome-wide and
gene-specific priors for marker associations.
3
2 Model
Here we describe our hierarchical model for gene-specific probabilities in gen-
eral, to convey its applicability to a wide variety of data types and Bayesian
models for association. Details specific to the methylation screening example in
Section 5 are given in Appendix A.
Suppose data are collected for M genetic or epigenetic markers from N
individuals, where each marker maps to one of G genes. Let Mg be the number
of markers that map to gene g, so that M =
∑G
g=1Mg. Let Xgmn denote data
for marker m in gene g (g ∈ 1, . . . ,Mg) for individual n, and let Yn define a
phenotypic response for individual n.
Let H0,gm define a probabilistic model of no association with Y for marker m
in gene g, and Ha,gm define the alternative model of association. The posterior
probability of the null for the given marker, P (H0,gm | X,Y ), is
P (H0,gm)P (X,Y | H0,gm)
P (H0,gm)P (X,Y | H0,gm) + P (Ha,gm)P (X,Y | Ha,gm) .
Under our proposed model, prior probabilities are equal within a gene:
pg = P (H0,gm) for m = 1, . . . ,Mg.
We use a nonparametric hyperprior to infer the gene-level prior probabilities
{pg}Gg=1 and borrow information across the genes. Specifically, the distribution
of the p′gs is a Dirichlet process [Ferguson, 1973] with a Beta(a, b) base dis-
tribution and concentration parameter α: pg ∼ DP(Beta(a, b), α). Under this
framework, each pg is drawn from a theoretically infinite number of realizations
θh from Beta(a, b), with corresponding probability weights pih:
pg ∼
∞∑
h=1
pihδθh ,
where δθh is a point mass at θh. A consequence of this model is clustering of
the genes, as values θh with larger weights pih will correspond to the probability
for several genes. This clustering property is useful for interpretation (e.g., to
identify gene sets) but our primary motivation for using the Dirichlet process is
to provide a sufficiently robust and flexible hierarchical distribution for the p′gs.
The concentration parameter α controls the dispersion of the weights pih and,
hence, influences the sizes of the gene clusters. As α→ 0 a single realization will
correspond to all genes (e.g., p1 = . . . = pG = θ1); hence, the limit is equivalent
to a genome-wide correction for multiplicity. As α→∞ each gene will have its
own realization (e.g., p1 = θ1, p2 = θ2, . . .); hence, the limit is equivalent to
a separate, independently estimated probability for each gene. In practice we
find that fixing α as a small positive value, such as α = 1, allows for sufficient
posterior flexibility between these two extremes.
It is also informative to consider the choice of a, b in the Beta base distribu-
tion. In applications where a Beta(a, b) distribution is used for a shared prior
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probability, fixing a = 1 is common [Scott et al., 2010]. Choosing b = λM , pro-
vides a natural multiplicity adjustment, as the expected number of associated
markers under the prior model is then 1/λ regardless of the number of markers
M [Wilson et al., 2010]. This result extends to our context, as E(pg) = a/b and
therefore the expected number of associated markers under the prior is
G∑
g=1
MgE(pg) = M · a
b
.
However, philosophically there may be little reason for the probability of as-
sociation at each marker to be negatively effected by the number of markers
measured. In practice we find that a simple uniform base distribution Beta(1, 1)
allows for substantial flexibility and still performs well as a multiplicity correc-
tion under a global null.
The parameter pg should not be interpreted as the overall probability of
association for gene g. Rather, it can be viewed as the inferred proportion of
locations within the gene that are associated. This is one approach to prioritize
genes, but more importantly the p′gs can improve the accuracy of posterior
inference at the marker level.
3 Inference
Here we describe a general Gibbs sampling scheme to compute the full posterior
under the gene-level prior model specified above. This estimation approach
is informative, illustrating how the marker parameters, gene parameters, and
global parameters relate to each other. Fundamentally, the algorithm proceeds
by sampling from the posterior of each marker, then updating the gene-specific
probabilities and their corresponding Dirichlet process parameters.
We use the constructive stick-breaking representation of the Dirichlet process
[Sethuraman, 1994] to sample from its full conditional distribution. That is, the
probability weights pih are generated by pih = Vh
∏
l<h(1 − Vl), where Vh iid∼
Beta(1, α). In practice we truncate the infinite mixture by a large integer H,
and perform blocked Gibbs sampling [Ishwaran and James, 2001]. Thus, letting
Cg define the cluster index for gene g (pg = θCg ), Cg ∈ {1, . . . ,H}. The weights
pih usually decrease quickly to very small values, and thus the effect of truncation
is negligible.
Assuming the marginal likelihoods under the null and alternative models
can be computed for each marker, sampling from the full conditionals proceeds
as follows:
1. Designate null markers H0,gm for g = 1, . . . , G, m = 1, . . . ,Mg. The
conditional probability of the null, P (H0,gm | X,Y, pg), is
pgP (X,Y | H0,gm)
pgP (X,Y | H0,gm) + (1− pg)P (X,Y | Ha,gm) .
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2. Allocate indices Cg for g = 1, . . . , G:
P
(
Cg = h | θh, {H0,gm}Mgm=1
)
∝ pihθSgh (1− θh)Mg−Sg
for h = 1, . . . ,H, where Sg is the number of null markers in gene g,
Sg =
∑Mg
m=1 1(H0,gm).
3. Update the weights pih for h = 1, . . . ,H. First, draw the stick-breaking
weights V1, . . . , VH−1. The full conditional distribution of Vh is
Beta
(
1 +
G∑
g=1
1(Cg = h), α+
G∑
g=1
1(Cg > h)
)
,
with VH = 1. Then set pih = Vh
∏
l<h(1− Vl) for h = 1, . . . ,H.
4. Update the atoms θh for h = 1, . . . ,H. The full conditional distribution
of θh is
Beta
(
a+ S˜h, b+ M˜h − S˜h
)
,
where M˜h is the total number of markers in genes allocated to cluster h,
and S˜h is the number of null markers:
M˜h =
∑
{g:Cg=h}
Mg , S˜h =
∑
{g:Cg=h}
Sg.
Set pg = θCg for g = 1, . . . , G.
Point estimates for the gene-level probabilities pg and marker posterior prob-
abilities P (H0,gm | X,Y ) can be obtained by averaging their draws over the
sampling iterations.
The marginal likelihoods under the null and alternative hypotheses in sam-
pling step 1 may not be feasible to compute directly. If not, additional sampling
steps can be incorporated to update model-specific parameters for each marker
under H0,gm and Ha,gm. Such an approach is used for the two-group methyla-
tion screening scenario described in Section 5.
4 Simulation Study
Here we present a simulation study to illustrate the advantages of our hierar-
chical model for gene-level probabilities. We compare our hierarchical approach
detailed in Sections 2 and 3 with three other approaches for inferring marginal
probabilities of the null at each marker:
• Separate estimation, in which a probability is inferred independently for
each gene, and shared by all markers for that gene.
• Joint estimation, in which a probability is inferred globally and shared by
all markers.
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• Simple estimation, in which the prior is fixed at 0.5 for all markers. This is
equivalent to independently considering the Bayes factor for each marker.
For simplicity, we assume marker values are binary (e.g., representing pres-
ence of the minor allele for genotype data). We simulate data for two groups,
each with 100 individuals (N = 200). For null markers, binary values are sim-
ulated under a common probability for both groups, where this probability is
drawn from a uniform distribution. For alternative markers, binary values are
simulated under a different probability for each group, where these probabilities
are drawn independently from a uniform distribution. The Bayes factor for the
null over the alternative for a given marker is then
β(1 + s1 + s2, 1 + 200− s1 − s2)
β(1 + s1, 1 + 100− s1)β(1 + s2, 1 + 100− s2) ,
where β defines the beta function, and s1 and s2 are the number of individuals for
which the marker is present in groups 1 and 2, respectively. This is analogous to
the prospective Bayes factor for SNP association testing introduced in Balding
[2006]. Data are simulated for G = 1000 genes, where the number of markers
within a gene Mg is drawn from {2, 3, . . . , 20} with equal probability.
We consider three different scenarios with dramatically different assumption
on the distribution of null and alternative markers across the genes. For each
scenario, we show the inferred distribution of the gene-specific probabilities pg
under the four methods considered. We also compute the expected overall
error in classifying null and alternative markers, as the average misclassification
probability over all markers.
First, we simulate data where the null is true for all markers, to illustrate
how the four methods perform as a multiplicity adjustment. Results are shown
in Figure 1A. The simple model with fixed prior probability of 0.5 performs
relatively poorly; in this and other simulations the average error in classifying
markers independently is approximately 20%. The joint and hierarchical mod-
els have negligible error, as they both borrow information globally to enforce
appropriately high prior probabilities of the null. The model with separately
inferred priors for each gene does not perform as well, as its shift toward the null
is relatively weak, especially for those genes with a small number of markers.
Second, we simulate data from a bimodal distribution in which the majority
of genes (80%) are null for all markers, but for a subgroup of genes (20%) the
alternative is true for all markers. Results are shown in Figure 1B. In this case
the hierarchical model performs well, as it identifies both modes and allocates
the appropriate genes to each mode. The separate model performs better than
the joint model, as the joint model does not account for the heterogeneity in
the genes. However, the separate model is not competitive with the hierarchical
model, as again the gene-specific probabilities have substantial uncertainty and
do not shrink toward the two modes if they are estimated independently.
Third, we simulate the gene-specific probabilities from a Beta(1, 0.2) distri-
bution, which has a majority of its mass near 1 (corresponding to genes in which
the vast majority of markers are null) but a long left tail. Results are shown in
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Figure 1C. The joint and separate models perform similarly, as the joint model
ignores the gene heterogeneity and the separate model exaggerates gene het-
erogeneity. The hierarchical model serves as a flexible compromise between the
two extremes, and closely approximates the true gene-specific probabilities.
To compare the Bayesian methods above with frequentist methods for mul-
tiple hypothesis testing, we compute a p-value for the null using Fisher’s exact
test at each marker. We consider the following multiplicity adjustments for
these p-values:
• Separate false-discovery rate (FDR) corrections for each gene, using the
Benjamini-Hochberg method [Benjamini and Hochberg, 1995].
• An overall FDR correction for each marker.
• A two-step hierarchical hypothesis testing framework [Li and Ghosh, 2014]
that uses the Hochberg [Hochberg, 1988] and Benjamini-Hochberg meth-
ods. This method controls the overall FDR while allowing for dependence
within sets of hypotheses. In our context, a set corresponds to markers
within a gene.
P-values and Bayesian posterior probabilities have fundamental differences
in philosophy and interpretation, and are not directly comparable. Nonethe-
less, for illustration we compare the various approaches above by considering
standard thresholds on the posterior probability, p-value or FDR that are used
to classify markers as null or alternative. For Bayesian methods we use 0.5 as
a threshold on the posterior probability, and for the frequentist methods we
use a significance threshold of α = 0.05. The resulting misclassification rates
under each simulation scenario are shown in Table 1. Under the null model
the hierarchical Bayesian approach gives very low error, similar to overall FDR
corrections. Under the two scenarios with alternative markers the Bayesian
hierarchical model performs substantially better than frequentist multiplicity
corrections, which are overly conservative.
Figure 2 gives receiver operating characteristic (ROC) curves showing the
proportion of markers with false positive or true positive classification (where
‘positive’ corresponds to the alternative) as the threshold on the posterior prob-
ability, p-value, or FDR is varied. Results are shown for the bimodal and Beta
simulations; the ROC curve for the null simulation is trivial, as there are no true
positives. In both cases the Bayesian hierarchical model has uniformly better
classification performance than alternatives. The ROC curves for separate esti-
mation are close, indicating that the rank ordering of probabilities are similar
despite the improved accuracy of the hierarchical model.
A spreadsheet available online gives results for 99 additional simulated datasets
with varying sample size, number of genes, and distribution of gene-level prob-
abilities. These results demonstrate the robustness of the hierarchical model.
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Figure 1: Comparison of four approaches to inferring prior probabilities, under
three simulation scenarios (A,B, and C). Kernel density estimates of the result-
ing gene-specific probabilities are shown for continuous distributions; discrete
distributions are shown by vertical lines. The distribution of the true gene-
specific probabilities is colored black. The expected overall error in classifying
null and alternative markers is also shown for each method and each simulation
scenario.
9
Table 1: Error in classifying null and alternative markers, using 0.5 as a thresh-
old for the posterior probability for Bayesian methods, and 0.05 as an FDR or
P-value threshold for frequentist methods using Fisher’s exact test. The average
over 50 replicate simulations is shown, and the resulting standard error is less
than 0.05% for all cells.
Null Bimodal Beta (1, 0.2)
Bayesian
Hierarchical 0.01% 0.07% 3.92%
Separate 0.50% 1.68% 4.87%
Joint 0.01% 6.89% 5.34%
Simple 5.07% 8.72% 7.82%
Frequentist
Two-step FDR 0.01% 7.73% 6.30%
Separate FDR 0.23% 5.64% 5.41%
Overall FDR 0.01% 7.15% 5.78%
No correction 2.91% 7.50% 6.49%
Figure 2: ROC curves obtained by varying the threshold on the posterior prob-
ability, p-value, or FDR for various methods. Curves are combined for the joint
and simple Bayesian models, and for the uncorrected p-value and FDR, as the
rank ordering of markers between these methods do not change.
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5 Application to LGG-GBM Methylation
We implement our hierarchical gene-level prior model in a screen for differences
in DNA methylation between lower grade gliomas (LGG) and glioblastoma mul-
tiforme (GBM) tumor samples that develop from astrocyte cells in the brain.
Methylation is an epigenetic phenomenon that occurs at cytosine-phosphate-
guanine (CpG) dinucleotide sites in the genome. Methylation is thought to
play a significant role in LGG pathogenesis [TCGA Research Network, 2015]
and GBM pathogenesis [TCGA Research Network, 2013], but the differences
between the two tumor classes have not been well-characterized on a genome-
wide scale. Both tumors are heterogenous and typically fatal, but a more com-
plete understanding of their molecular differences is important, as LGGs often
progress to GBMs and GBM patients have a much shorter survival time.
We use data from the Illumina HumanMethylation450 array, for 128 astro-
cyte derived LGG samples and 130 GBM samples, from The Cancer Genome
Atlas. Measured CpG sites that have any missing data are removed, as are sites
that map to intergenic regions. After filtering, 294, 093 CpG sites remain, that
map to 24, 358 distinct genes. The number of sites in a gene ranges broadly
from 1 to 1017. Array values at each site are between 0 (no methylation) and 1
(fully methylated across all cells in the tumor sample).
Several computational methods have been developed to screen for differen-
tial methylation levels between groups, based on array data [Jaffe et al., 2012,
Maksimovic et al., 2015] or sequencing data [Sun et al., 2014, Feng et al., 2014,
Wu et al., 2015]. However, the focus on differential methylation levels between
groups may miss other important differences between group distributions; for
example, certain genomic regions have been shown to exhibit more variability in
methylation, and hence greater epigenetic instability, among cancer cells than
among normal cells [Hansen et al., 2011].
We test for differences in distribution between the LGG and GBM samples
at each CpG site. Our testing model is described in detail in Lock and Dun-
son [2015], where it is implemented on comparatively sparse methylation data
(≈ 20, 000 sites) with a global prior and shown to compare favorably to frequen-
tist and Bayesian alternatives. Briefly, the distribution at each site is modeled
as a mixture of normal kernels, truncated between 0 and 1. The kernels are
shared across CpG sites, and thus capture shared patterns of multi-modality
and skewness that are typical in methylation array data. Under the null the
kernel mixing weights at each site are assumed to be the same between the two
groups, and under the alternative they are different. This provides a robust
and consistent framework for testing differential distribution, and can identify
important differences that are not captured by simply comparing mean methy-
lation levels. Furthermore, the method facilitates interpretation by modeling
the full distribution, with uncertainty, for each class. We incorporate hierarchi-
cal gene-level priors within the shared kernel testing model, and compute the
full posterior via Gibbs sampling.
The estimated gene-level probabilities are shown in Figure 3. Their distri-
bution resembles that in the simulation shown in Figure 1C. For the majority
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Figure 3: Histogram of estimated gene-specific probabilities pg.
of genes the distribution between the two groups is inferred to be equal at most
sites (pg ≈ 1). However, there is a substantial left tail, corresponding to genes in
which a large number of sites are inferred to differ between the two groups. For
illustration we focus on one such gene, BST2, which has 9 measured CpG sites
and an estimated gene-level probability of pg = 0.198. We select BST2 because
it has been considered as a tangible target for immunotherapy in the treatment
of GBM [Etcheverry et al., 2010], an independent comparison of GBM and nor-
mal samples found differences in BST2 methylation that correlate with gene
expression [Wainwright et al., 2011], and BST2 methylation may play a role in
the pathonogenesis of other cancers [Mahauad-Fernandez et al., 2014]. Figure 4
shows the genomic location and posterior probability of group equality for the
nine CpG sites in BST2, as well as group histograms and posterior densities for
methylation at three sites.
Given the large number of CpGs and corresponding genes with differential
methylation distribution, we also investigate differences at a macro level. Fig-
ure 5 shows the site means and standard deviations within each group, for those
sites with a posterior probability of equality less than 0.01 (24.6% of all CpGs).
Mean methylation levels at these sites are generally greater in the LGG samples
than the GBM samples; this is concordant with findings in a smaller compar-
ison of 1536 CpG sites in 807 genes [Laffaire et al., 2011]. The distribution of
standard deviations is more curious, as LGG samples show a larger number of
sites with either very high variability or very low variability in comparison to
the distribution for GBM.
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Figure 4: The top panel shows the estimated posterior probability of an associ-
ation with GBM-LGG status for the 9 CpG sites measured in the gene BST2,
with their corresponding genomic location. The lower panel shows the estimated
densities for the GBM (blue) and LGG (red) groups for three sites; histograms
of each group are shown, and their overlap is colored purple.
Details regarding the association model and Gibbs sampling algorithm for
posterior computation are given in Appendix A.
5.1 Validation
To asses the appropriateness of the hierarchical gene-level model, we consider
the agreement of estimated gene-level probabilities and marker-level posteri-
ors under cross validation. Specifically, we randomly select 10, 000 CpGs to
leave out, and compute gene-level probabilities using the remaining 284, 093
CpGs. For each left out CpG, we measure the Kullback-Leibler divergence of
its estimated gene-level probability under the reduced data from its CpG-level
posterior probability under the full data. This can be interpreted as the gain of
information or degree of “surprise” between a CpG’s posterior probability and
its gene-level prior [Lindley, 1956]. We repeat this process using a separately es-
timated prior probability for each gene, a single inferred prior probability, and a
prior probability of 0.5 (corresponding to the separate, joint and simple models
in the Simulation Study). The hierarchical model yields the greatest agree-
13
Figure 5: Histograms of summary statistics for every CpG site with a posterior
probability of the null less than 0.01, computed separately for the GBM (dark
gray) and LGG (light gray) groups. Overlap between the two histograms is
colored a neutral gray. The left panel show the site means, the right shows the
site standard deviations.
ment, with a mean Kullback-Leibler divergence of 0.451; the separate model
has a divergence of 0.482, the joint model 0.560, and the simple model 0.654.
We also conduct two permutation studies, to further assess the appropriate-
ness and flexibility of our gene-level model. First, we randomly permute the
gene labels for each marker, so that there is no true gene-level dependence. The
subsequent posterior means for the gene level prior probabilities pg are shown
in the top-left panel of Figure 6. The estimates converge appropriately to a
single global probability near 0.72, in sharp contrast to the relatively dispersed
estimates using the true data in Figure 2 of the main article. Second, we ran-
domly permute the class labels but maintain the true gene labels, to generate a
dataset with a global null but gene-level dependence. The subsequent posterior
estimates are shown in the top-right panel of Figure 6, and cluster very close to
1. In fact, all 294, 093 estimated site-specific posterior probabilities of the null
are greater than 0.5. Together, these results demonstrate that the hierarchical
gene-level model appropriately shrinks gene-level priors toward a global pattern.
The estimated hierarchical gene-level probabilities closely approximate a sin-
gle joint prior probability in Figure 6, where a joint prior is appropriate, but
not for the true data. Thus, we conclude that a single joint model is an over-
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Figure 6: Histogram of hierarchically estimated and separately estimated gene-
level priors after randomly permuting gene labels (left column), and after ran-
domly permuting class labels (right column).
simplification for these data. We also compare the hierarchical gene-level prior
probabilities under permutation with separate, independently estimated gene-
level probabilities. The separately estimated probabilities are shown in the bot-
tom row of 6. These have a lot of variability under both permutation scenarios,
illustrating how independent consideration of the genes sacrifices accuracy by
exaggerating gene effects.
6 Discussion
Borrowing information and incorporating prior knowledge in a principled and
computationally feasible way is an important challenge for Bayesian genome-
and epigenome-wide screening methods. Here we present a flexible and gener-
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ally applicable hierarchical model for inferring gene-specific probabilities, which
may be extended in several ways. Under our prior all markers within a gene have
an equivalent probability of association. The incorporation of other marker-level
information, such as gene promoter status for DNA methylation [Weber et al.,
2005] or functional annotation (e.g., synonymous vs. non-synonymous) for geno-
type markers [Kichaev et al., 2014, Ruklisa et al., 2015], may improve posterior
precision and interpretation. For example, a Dirichlet process model may be
used for gene-level intercepts within a regression model for marker probabilities
that includes additional prior covariates [Lewinger et al., 2007]. Incorporat-
ing additional gene-level prior information, such as allowing greater dependence
within known functional gene networks [Zhang et al., 2014], is also a promising
direction of future work.
Our focus is on association testing. However, markers that are statistically
associated with a given phenotype may not affect the phenotype directly, espe-
cially if markers are correlated (e.g., linkage disequilibrium in genetic data). Our
gene-specific model and other prior information can also be used in the context
of model inclusion probabilities, to select markers that have novel predictive
power for a given phenotype and are therefore more likely to be causal [Wilson
et al., 2010, Zhang et al., 2014, Duan and Thomas, 2013]. However, computa-
tional scaling for high-throughput data is often a challenge in such problems;
alternatively, markers identified via association testing may subsequently be in-
cluded as phenotype predictors in a second stage model [Yazdani and Dunson,
2015].
In our context we consider multiple hypotheses, in which the hypotheses are
naturally grouped by markers within a gene, but there are similar scenarios in
other areas of genomics research. For example, when screening multiple genes
for a phenotypic association (e.g., via microarray or RNA-seq data) the genes
can be partitioned into groups based on pathways or other prior information.
Frequentist methods that provide appropriate type I error control over genes
and gene sets have been developed [Benjamini and Heller, 2008, Heller et al.,
2009, Li and Ghosh, 2014], and these methods can be generalized to other prob-
lems that involve testing hypotheses over multiple sets. Broadly, our proposed
model defines a general prior for multiple hypothesis testing within a Bayesian
framework when the hypotheses can be partitioned into sets.
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A Posterior Computation
This appendix provides details on posterior computation for the methylation
screening application described in Section refapp.
First, we estimate and fix a dictionary of normal kernels truncated between
0 and 1, which will be used as mixture components for the density at each
CpG site. These are estimated as described in Section 5 of Lock and Dunson
[2015]. In particular, the number of kernels is determined by out-of-sample cross
validation of the log posterior density. For the present application this yields
K = 8 kernels that appropriately span the data range from 0 to 1.
Let Π
(0)
gm = (pi
(0)
gm1, . . . , pi
(0)
gmK) be the kernel probability weights that define
the generative distribution for gene g and site m for group 0, and let Π
(1)
gm be the
kernel probability weights for group 1. Under the null model H0gm, the mixing
weights are the same for both groups: Π
(0)
gm = Π
(1)
gm. The kernel weights are
assumed to be generated from a Dirichlet(λ) distribution, where λ is a hyper-
parameter that is inferred during the kernel estimation stage and fixed. Under
H1gm, Π
(0)
gm and Π
(1)
gm are considered independent realizations from Dirichlet(λ).
Under this framework, posterior draws from the gene-level prior model de-
scribed in Section 3 of the main article are incorporated into Gibbs sampling for
the kernel testing parameters. The full sampling algorithm is described below.
1. Draw the kernel that generated each observation T
(i)
gmn ∈ 1, . . . ,K for
genes g = 1, . . . , G, markers m = 1, . . . ,Mg, classes i = 0, 1 and samples
n = 1, . . . , Ni. The conditional probability that the given value is realized
from component k is
P (T (i)mn = k | X(i)m ,Π(i)m ) ∝ pi(i)gmkf(X(i)gmn|µk, σk, [0, 1]),
where f(·) defines the density of a truncated normal distribution.
2. Designate null markers H0,gm for g = 1, . . . , G, m = 1, . . . ,Mg. The
conditional posterior probability is
P (H0,gm | X,Y, pg) = pgβ(λ)β(~nm + λ)
pgβ(λ)β(~nm + λ) + (1− pg)β(~n(0)m + λ)β(~n(1)m + λ)
,
where ~n
(0)
gm = (n
(0)
gm1, . . . , n
(0)
gmK) is the number of subjects in group 0 that
belong to each kernel k in marker g,m, ~n
(1)
gm is defined similarly for group
1, and ~ngm = ~n
(0)
gm + ~n
(1)
gm.
3. Draw weights {Π(0)gm,Π(1)gm}Mm=1. Under H0,gm, Π(0)gm = Π(1)gm ∼ Dirichlet(λ+
~ngm). Otherwise, Π
(0)
gm ∼ Dirichlet(λ + ~n(0)mg) and Π(1)gm ∼ Dirichlet(λ +
~n
(1)
mg).
4. Allocate gene-level Dirichlet indices Cg for g = 1, . . . , G:
P (Cg = h | θ·, H0,g·) ∝ pihθSgh (1− θh)Mg−Sg
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where Sg is the number of null markers in gene g, Sg =
∑Mg
m=1 1(H0,gm).
5. Update the weights pih for h = 1, . . . ,H. First, draw the stick-breaking
weights V1, . . . , VH−1 by
(Vh | C·) ∼ Beta
(
1 +
G∑
g=1
1(Cg = h), α+
G∑
g=1
1(Cg > h)
)
,
with VH = 1. Then set pih = Vh
∏
l<h(1− Vl) for h = 1, . . . ,H.
6. Update the atoms θh for h = 1, . . . ,H:
(θh | C·, H0,··) ∼ Beta
(
a+ S˜h, b+ M˜h − S˜h
)
,
where M˜h is the total number of markers in genes allocated to cluster h,
and S˜h is the number of null markers:
M˜h =
∑
{g:Cg=h}
Mg , S˜h =
∑
{g:Cg=h}
Sg.
Set pg = θCg for g = 1, . . . , G.
We use a simple uniform prior for the base distribution of pg (a = b = 1).
For the high-throughput data considered, computing is not trivial, costing
approximately 30 seconds per Gibbs cycle. However, less than 1% of computing
time is spent on the draws for the gene-level prior parameters (steps 4-6). We
find that draws mix well and converge very quickly to a stationary posterior.
We run two parallel chains, with different initializations, for 1000 cycles, with
the first 200 treated as burn-in. Figure 7 shows good agreement of estimated
gene-level prior probabilities between the two chains.
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Figure 7: Scatterplot of estimated gene-level prior from two independent sam-
pling chains.
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